Cargando…

Efficacy and Potential Positioning of Tezepelumab in the Treatment of Severe Asthma

The excellent results for monoclonal antibodies in the treatment of severe uncontrolled asthma (SUCA) represent a milestone in current treatment of asthmatic disorders. Remaining, however, are several subsidiary areas for improvement in which new biologics are expected to make a decisive contributio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Plaza, Vicente, Cañete, Conxa, Domingo, Christian, Martínez Rivera, Carlos, Muñoz, Xavier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369521/ https://www.ncbi.nlm.nih.gov/pubmed/37496871 http://dx.doi.org/10.1016/j.opresp.2022.100231

Ejemplares similares

Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma
por: Pelaia, Corrado, et al.
Publicado: (2021)

The potential promise and challenge for tezepelumab as a biologic therapy for severe asthma
por: Williams, Dennis M
Publicado: (2022)

Dupilumab and tezepelumab in severe refractory asthma: new opportunities
por: Ragnoli, Beatrice, et al.
Publicado: (2022)

Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR
por: Laidlaw, Tanya M, et al.
Publicado: (2023)

Tezepelumab as an Emerging Therapeutic Option for the Treatment of Severe Asthma: Evidence to Date
por: Dorey-Stein, Zachariah L, et al.
Publicado: (2021)

Mapping Impossible Utilities: The ICER Report on Tezepelumab for Severe Asthma
por: Langley, Paul C
Publicado: (2022)

Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR [Corrigendum]
Publicado: (2023)

Molecular Targets for Biological Therapies of Severe Asthma: Focus on Benralizumab and Tezepelumab
por: Cheng, Shih-Lung
Publicado: (2021)

Baseline type 2 biomarker levels and response to tezepelumab in severe asthma
por: Corren, Jonathan, et al.
Publicado: (2022)

Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab
por: van Dijk, Yoni E., et al.
Publicado: (2023)

Tezepelumab for Patients with Severe Uncontrolled Asthma: A Systematic Review and Meta-Analysis
por: Zoumot, Zaid, et al.
Publicado: (2022)

The Impact of Tezepelumab in Uncontrolled Severe Asthma: A Systematic Review of Randomized Controlled Trials
por: Roy, Pooja, et al.
Publicado: (2022)

Tezepelumab treatment for allergic bronchopulmonary aspergillosis
por: Ogata, Hiroaki, et al.
Publicado: (2023)

Safety and efficacy of tezepelumab vs. placebo in adult patients with severe uncontrolled asthma: a systematic review and meta-analysis
por: Shaban Abdelgalil, Mahmoud, et al.
Publicado: (2022)

Effect of Tezepelumab on Lung Function in Patients With Severe, Uncontrolled Asthma in the Phase 3 NAVIGATOR Study
por: Menzies-Gow, Andrew, et al.
Publicado: (2023)

The efficacy and safety of tezepelumab in the treatment of uncontrolled asthma: A systematic review and meta-analysis of randomized controlled trials
por: Lin, Fei, et al.
Publicado: (2023)

Disconnect for Tezepelumab on Exacerbations, Symptoms, and Quality of Life in Type 2 Low Asthma
por: Lipworth, Brian, et al.
Publicado: (2023)

Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?
por: Menzies-Gow, Andrew, et al.
Publicado: (2020)

Functionality and Performance of an Accessorized Pre-Filled Syringe and an Autoinjector for At-Home Administration of Tezepelumab in Patients with Severe, Uncontrolled Asthma
por: Alpizar, Sady, et al.
Publicado: (2021)

Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma with and without Nasal Polyposis: A Post Hoc Analysis of the Phase 2b PATHWAY Study
por: Emson, Claire, et al.
Publicado: (2021)

The effectiveness and value of tezepelumab for severe asthma: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Rind, David M, et al.
Publicado: (2022)

NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma
por: Menzies-Gow, Andrew, et al.
Publicado: (2020)

Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study
por: Corren, Jonathan, et al.
Publicado: (2021)

Comparative Efficacy and Safety of Tezepelumab and Other Biologics in Patients with Inadequately Controlled Asthma According to Thresholds of Type 2 Inflammatory Biomarkers: A Systematic Review and Network Meta-Analysis
por: Ando, Koichi, et al.
Publicado: (2022)

Clinical characteristics in 545 patients with severe asthma on biological treatment during the COVID-19 outbreak
por: Rial, Manuel Jorge, et al.
Publicado: (2021)

Pharmacokinetics, Safety, and Tolerability of Tezepelumab (AMG 157) in Healthy and Atopic Dermatitis Adult Subjects
por: Parnes, Jane R., et al.
Publicado: (2019)

Is asthma in the elderly different? Functional and clinical characteristics of asthma in individuals aged 65 years and older
por: Curto, Elena, et al.
Publicado: (2019)

DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma
por: Menzies-Gow, Andrew, et al.
Publicado: (2020)

CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma
por: Emson, Claire, et al.
Publicado: (2020)

SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma
por: Wechsler, Michael E., et al.
Publicado: (2020)

Dual Monoclonal Antibody Therapy for a Severe Asthma Patient
por: Domingo, Christian, et al.
Publicado: (2020)

Prevalence of modifiable factors limiting treatment efficacy of poorly controlled asthma patients: EFIMERA observational study
por: Ribó, Paula, et al.
Publicado: (2020)

The respiratory microbiome in bronchial mucosa and secretions from severe IgE-mediated asthma patients
por: Millares, Laura, et al.
Publicado: (2017)

Efficacy of tamoxifen for the treatment of severe equine asthma
por: Mainguy‐Seers, Sophie, et al.
Publicado: (2018)

The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma–COPD Overlap Syndrome
por: Pérez de Llano, Luis, et al.
Publicado: (2022)

Nasal polyps, aspirin sensitivity, and late onset asthma are crucial to identify severe asthma. clinicaltrials.gov id : nct01513837
por: Castillo, José A, et al.
Publicado: (2015)

Analysis of Differentially Expressed MicroRNAs in Serum and Lung Tissues from Individuals with Severe Asthma Treated with Oral Glucocorticoids
por: Gil-Martínez, Marta, et al.
Publicado: (2023)

Characterization and Factors Associated with Poor Asthma Control in Adults with Severe Eosinophilic Asthma
por: Padró-Casas, Clara, et al.
Publicado: (2023)

Efficacy of inhaled budesonide for the treatment of severe equine asthma
por: Lavoie, J. P., et al.
Publicado: (2018)

A Phase 1, Randomized, Placebo‐Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Subcutaneous Tezepelumab in Healthy Japanese Men
por: Sakamoto, Kei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2ad2brqkkcnlr2i0qahcq7jp3m